Hemophilia is it a genetic disorder where the body doesn’t produce clotting factor, which means blood can’t clot. This makes patients susceptible to both heavy external and internal bleeding, which if left untreated, can be life-threatening. Thanks to Hemophilia Village, we have the answers to some of the most commonly…
Search results for:
Factor VIII (FVIII) replacement therapy is a cornerstone of treatment for many people with hemophilia A, a rare bleeding disorder caused by deficient or dysfunctional FVIII, a protein needed for blood clotting. Because people with hemophilia A have reduced FVIII activity, they are prone to prolonged bleeding…
Efanesoctocog alfa, a long-lasting factor VIII (FVIII) replacement therapy, has now been approved in the European Union for hemophilia A. It will be marketed under the brand name Altuvoct. Altuvoct can be used as an on-demand treatment for bleeding episodes, a once-weekly prophylactic (preventive) therapy to reduce the…
Afstyla (lonoctocog alfa) is an injectable factor replacement therapy used to prevent and treat bleeding episodes, including those occurring during surgery, in people with hemophilia A.
Voncento — a highly concentrated mixture of Von Willebrand factor (VWF) and clotting factor VIII (FVIII) — was seen to safely and effectively treat or prevent bleeds in children, age 12 and younger, with severe hemophilia A, according to data from a Phase 3 trial. Findings were reported in the…
In real-world settings, Hemlibra (emicizumab-KXWH) can safely control bleeds in children with hemophilia A better than previous treatment regimens, a study reports. Hemlibra’s improved efficacy was more pronounced among patients with inhibitors, or neutralizing antibodies targeting factor VIII (FVIII), which is the clotting protein missing in people with…
Gene constructs making up Roctavian, an investigational gene therapy for hemophilia A, did not permanently integrate into the genome of non-human primates or cause any signs of tumors or malignancy in the animals. These are…
The U.S. Food and Drug Administration (FDA) has cleared for laboratory use CRYOcheck Factor VIII Deficient Plasma with VWF, a way of detecting factor VIII (FVIII) deficiency in blood samples. Now available in the U.S., Precision Biologic’s manufactured plasma — the liquid part of blood that…
The levels of sclerostin, a protein that regulates bone formation, may be linked to disease severity and reflect bone alterations in children with hemophilia A, a study suggests. The study, “Serum Sclerostin Level and Bone Mineral Density in Pediatric Hemophilic Arthropathy,” was published in The Indian…